1
|
Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med 2017; 6:902-909. [PMID: 28414866 PMCID: PMC5430092 DOI: 10.1002/cam4.1048] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 01/21/2017] [Accepted: 02/02/2017] [Indexed: 12/19/2022] Open
Abstract
Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression‐free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor‐risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.
Collapse
Affiliation(s)
- John Connor Wells
- Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.,Queen's University, Kingston, Ontario, Canada
| | | | | | - Felice Pasini
- Medical Oncology Department, Ospedale Santa Maria della Misericordia, Rovigo, Italy
| | | | | | | | - Sun Young Rha
- Yonsei University College of Medicine, Seoul, South Korea
| | - Neeraj Agarwal
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | | | - Jae-Lyun Lee
- Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
| | - Sumanta K Pal
- City of Hope Comprehensive Cancer Center, Duarte, California
| | | | | | | | - Lori A Wood
- Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
| | - Robin Simpson
- Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
| | | | | | - Daniel Y C Heng
- Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|